

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
**WO 01/42298 A1**

- (51) International Patent Classification<sup>7</sup>: C07K 14/00, (74) Agent: FUESS, William, C.; Fuess & Davidenas, Suite A61K 38/00 II-G, 10951 Sorrento Valley Road, San Diego, CA 92121 (US).
- (21) International Application Number: PCT/US00/07380
- (22) International Filing Date: 20 March 2000 (20.03.2000)
- (81) Designated States (*national*): AU, CA, JP.
- (25) Filing Language: English
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (26) Publication Language: English
- (30) Priority Data: 09/454,223 9 December 1999 (09.12.1999) US
- Published:  
— With international search report.
- (71) Applicant and  
(72) Inventor: KORNBLUTH, Richard, S. [US/US]; 5415 Taft Avenue, La Jolla, CA 92037 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/42298 A1

(54) Title: MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS

(57) Abstract: A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.

## MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS

### 5 BACKGROUND OF THE INVENTION

#### Field of the Invention

The present invention relates to a method form preparing soluble multimeric proteins consisting of more than three iterations of the same bioactive  
10 molecule using recombinant DNA technology.

The present invention particularly concerns a new method of producing multimeric fusion proteins involving the TNF superfamily (TNFSF) members as a fusion proteins with SPD, and more specifically, CD40L-SPD fusion proteins  
15 and useful modifications thereof.

#### Description of Related Art

Numerous proteins can be made using modern molecular biology techniques and used in diagnostic and therapeutic applications. Using  
20 recombinant DNA techniques, the DNA encoding a single amino acid chain is constructed and then introduced into a cell which manufactures the final protein. Some cells, especially bacteria like *E. coli*, lack the ability to properly fold the amino acid chains into the proper quaternary structure and they often fail to apply the necessary modifications (e.g., glycosylation and disulfide bond formation) that  
25 are needed for the protein to be bioactive and resistant to degradation *in vivo*. While most of these challenges can be met by expressing the amino acid chain in eukaryotic cells like yeast or mammalian cells *in vitro*, it is not always straightforward to express proteins that consist of two or more amino acid chains. In general, for multichain proteins, the single amino acid chains must associate  
30 together in some way either within the producer cell or subsequently after the

monomers are secreted from the producer cell. For artificially constructed molecules, the introduction into a single amino acid chain of an amino acid sequence which causes this chain-to-chain association can be an important step in producing multichain proteins.

5

One of the most widely used methods of causing two amino acid chains to associate is to conjoin, at the DNA coding level, segments from the protein of interest and a segment from a spontaneously dimerizing protein. The best example is to conjoin or fuse a protein with the Fc portion of immunoglobulin, creating a dimeric Fc fusion protein (Fanslow *et al.*, *J. Immunol.* 136:4099, 1986). A protein of this type can be formed from the extracellular domain of a tumor necrosis factor receptor fused to Fc (termed etanercept and marketed as ENBREX<sup>®</sup>), which is effective in the treatment of rheumatoid arthritis. A second example is the construction of a fusion protein between the dimerizing extracellular portion of CD8 with the extracellular portion of CD40L (Hollenbaugh *et al.*, *EMBO J.* 11:4313, 1992). Here, the dimerizing CD8 portion of the fusion protein helps to maintain the CD40L portion in the trimeric form needed for its bioactivity. A more recent example is the addition of an isoleucine zipper motif to CD40L, which permits the production of trimeric soluble CD40L molecules (Morris *et al.*, *J. Biol. Chem.* 274:418, 1999).

The TNF superfamily (TNFSF) consists of an expanding number of proteins (see Table I) which are crucial for the development and functioning of the immune, hematological, and skeletal systems. TNFSF proteins are ligands for a corresponding set of receptors of the TNF receptor superfamily (TNFRSF). All TNFSF members are expressed as Type II membrane proteins, with the exception of lymphotoxin-alpha which is produced as a secreted protein. However, soluble forms of several TNFSF proteins can be released from the cell surface by proteolytic cleavage, usually by specific metalloproteinases.

The production of soluble forms of TNFSF proteins has been an important step in the study of these proteins. Soluble TNFSF ligands can be used to study the activities of these proteins in vitro without the complexities in interpretation that result when cells or cellular membranes expressing TNFSF proteins are added. In addition, soluble forms of several TNFSF proteins have potential as therapeutic agents for human diseases. In particular, TNF- $\alpha$  has been extensively studied for the treatment of cancer and soluble CD40L is currently undergoing clinical trials to assess its antitumor effects.

10

To produce soluble forms of TNFSF proteins, either the membrane protein is expressed in a cell line possessing a protease capable of separating the TNFSF extracellular domain from the transmembrane domain or a truncated form of the TNFSF protein is produced which consists solely of the extracellular domain plus a signal sequence. In either case, certain soluble forms of TNFSF proteins are unstable in solution as simple homotrimers composed solely of the extracellular domain. For example, naturally solubilized TNF- $\alpha$  is labile under physiological conditions [Schuchmann, 1995 #129]. To solve this stability problem, chimeric proteins have been constructed according to one of four different design principles: (1) The extracellular portion of the TNFSF protein has been expressed fused to the dimeric portion of the immunoglobulin Fc fragment US Patent 5,155,027, Oct. 13, 1992, issued to, Andrzej Z. Sledziewski, et al. In the case of CD40L and OX40L, this yields a soluble molecule which is significantly less active than the native membrane form of this protein. (2) The extracellular portion of the TNFSF protein has been expressed with an antigenic tag (usually the FLAG motif) fused to its N-terminus [Mariani, 1996]. The addition of an antibody to the tag (e.g., anti-FLAG antibody) aggregates these proteins into a multimeric form. Crosslinking enhances activity on B cells. (3) The extracellular portion of the TNFSF protein has been expressed fused to the spontaneously

25

dimerizing extracellular portion of the CD8 molecule [Hollenbaugh, 1992 ]. In the case of CD40L, this creates a hexameric molecule [Pullen, 1999 ] which is likely formed by two CD40L trimers attached to three CD8 dimeric stalks. Despite this, the addition of an anti-CD8 antibody to crosslink the CD40L-CD8 fusion protein yields a further enhancement of CD40L activity on B cells. (4) The extracellular portion of the TNFSF protein has been expressed fused to a trimerizing isoleucine zipper which maintains the overall trimeric structure of the protein [US Patent 5,716,805, Feb. 10, 1998, issued to Subashini Srinivasan et al. This soluble CD40L trimer or 'sCD40LT' is the form of that protein now being clinically tested in humans for its anti-tumor effects.

Compounding the difficulties in producing stable forms of soluble TNFSF proteins are compromises in bioactivity. As exemplified by FasL, TNF, and CD40L, many of the soluble forms of these proteins lack the full range of stimulatory activities displayed by the membrane forms of these molecules. For FasL, several groups have reported that naturally produced soluble FasL (generated by proteolytic cleavage from the membrane form) has a spectrum of activities that is distinctly different from the membrane form. Soluble FasL induces apoptosis in activated CD4+ T cells but not fresh, resting CD4+ T cells. In contrast, both types of CD4+ T cells are killed by membrane FasL or a recombinant soluble form of FasL (WX1) that spontaneously aggregates into oligomers larger than a decamer. For TNF, T cell activation through stimulation of TNFR II, the 80 kDa receptor for TNF, is much greater with membrane TNF than soluble TNF. However, if soluble TNF is produced as a tagged protein and crosslinked with an antibody against the tag, then it completely mimics the activities of membrane TNF [Schneider, 1998]. Finally, for CD40L, the stimulatory effects of a soluble form of this TNFSF protein are enhanced by crosslinking [Kehry, 1994] and yields an activity similar to membrane CD40L. For example, soluble CD40L-CD8 fusion protein requires crosslinking with a

antibody to CD8 in order to drive resting B cells to proliferate to a degree similar to membrane-bound CD40L. ). Even more strikingly, although membrane-bound CD40L expressed on baculovirus-transduced SF9 insect cells is a strong B cell stimulus, small vesicles (10 - 1,500 nm) prepared from the membranes of these cells are less stimulatory. However, ultracentrifugation of these vesicles creates aggregates which have the full activity of the original membrane CD40L protein. This indicates that B cells are more highly stimulated by a large surface of CD40L than they are by a smaller surface expressing this membrane ligand.

10 Taken together, the above reports suggest that, for some TNFSF/TNFRSF ligand/receptor pairs at least, it is essential to cluster receptors together for full signaling activity. By this interpretation, the efficacy of the membrane forms of FasL, TNF, and CD40L occurs because these ligands can move in the plane of the membrane toward the contact zone with a receptor-bearing responding cell, thereby clustering ligated receptors to form a receptor-dense region of the membrane. This interpretation is further supported by experiments where crosslinking of a soluble TNFSF protein effectively mimics the activity of the membrane form of the protein [Scheider, 1998].

20 In all of the above examples, no more than three amino acid chains have been caused to associate together. There is a need to produce multimeric protein molecules where more than three amino acid chains are caused to associate into a single soluble molecular complex. An important example comes from studies of CD40L (also called CD154 or TNFSF5), which is a member of the TNF family of molecules that are normally expressed as insoluble, cell membrane proteins. It has been shown that soluble homotrimers composed of the extracellular regions of CD40L, TNF, and FasL are not potently active on resting cells that bear receptors for these proteins. However, if these proteins are expressed with a tag on their ends (e.g., the FLAG peptide sequence) and then the trimers are extensively

crosslinked using an antibody to FLAG, full activity appears (Schneider *et al.*, *J. Exp. Med.* 187:1205, 1998). From this, it can be inferred that the soluble single-trimer forms of these molecules does not duplicate the multivalent interactions that normally occur when a receptor-bearing cell comes in contact with the  
5 membrane of a cell expressing numerous ligand trimers on its surface. This distinction may be due to a need for receptor clustering for full signaling (Bazzoni and Beutler, *N. Engl. J. Med.* 334:1717, 1996), which in turn is only possible with a multimeric ligand engaging many receptors at the same time in a localized region of the cell membrane.

10

### SUMMARY OF THE INVENTION

The present invention contemplates a method of preparing soluble, multimeric mammalian proteins by culturing a host cell transformed or transfected  
15 with an expression vector encoding a fusion protein comprising the hub, body, and neck region of a collectin molecule and a heterologous mammalian protein.

In one embodiment, the heterologous mammalian protein comprises an extra cellular domain of a mammalian transmembrane protein; the resulting fusion  
20 protein forms a multimer.

In another embodiment, the heterologous mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms a multimer.

25 In another embodiment, sites of proteolytic degradation are included or removed from the fusion protein; the resulting fusion protein forms a multimer from which are cleaved single units at a rate made variable by the nature of the proteolytic digestion sites either included or excluded.

In yet another embodiment, special attention is given to the immunogenicity of the fusion protein by altering the junction between the two naturally occurring proteins from which it is made; the resulting fusion protein may be less or more able to elicit an immune response against itself, which could  
5 lengthen its persistence or contribute to its immunological effectiveness.

A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD fusion protein, said structural gene having a nucleotide  
10 base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5 is disclosed by this invention. In one embodiment, the DNA segment the structural gene has a sequence expressing a single hybrid amino acid chain of TNFSF-SPD, the segment having a first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and a  
15 second sequence, expressing a portion of TNFSF stalk, selected from members of the group consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to base 1528, and SEQ ID NO 5, from base 800 to base 1441.

In another embodiment, a recombinant DNA molecule has vector  
20 operatively linked to an exogenous DNA segment defining a structural gene expressing a single amino acid chain of TNFSF-SPD. This structural gene has a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any functional equivalents and modifications thereof. There is also attached an appropriate promoter for driving  
25 the expression of said structural gene in a compatible host organism. The organism can be *E. coli*, a yeast, a higher plant or animal.

Yet another embodiment contemplated by the invention is multimeric TNFSF-SPD fusion protein having a plurality of polypeptide trimers, a first



trimer consisting of peptide strands of members of the TNF superfamily (TNFSF) of ligands, and a second trimer strand from a collectin molecule, each first trimer conjoined to a second polypeptide trimer strand from a collectin molecule, wherein said ligand strand is substituted for native carbohydrate recognition domains (CRD) of the collectin molecules. The conjoined collectin strands are covalently bound in parallel to each other, forming a multimeric fusion protein comprising a plurality of trimeric hybrid polypeptide strands radiating from a covalently bound center hub of the molecule. The free end of each trimeric radiating strand has a TNFSF moiety attached. The TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as shown in Table II, and their functional equivalents, and modifications thereof.

The invention also contemplates a method for preparing a CD40-SPD multimeric fusion polypeptide, including the steps of initiating a culture, in a nutrient medium, of procaryotic or eucaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for the cells, operatively linked to an exogenous DNA segment defining a structural gene for CD40-SPD ligand. The structural gene has a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about base 1444. Thereafter, the culture is maintained for a time period sufficient for the cells to express the multimeric molecule.

Also contemplated is a method of producing a secreted, very large, biologically active, multimeric tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusable. The steps for this method are as follows:

1. introducing into a host cell a first chimeric DNA construct including a transcriptional promoter operatively linked to a first secretory signal sequence,

followed downstream by, and in proper reading frame with a first DNA sequence encoding a polypeptide chain of a first TNFSF ligand requiring multimerization for biological activity. This sequence is joined to a second DNA sequence encoding a collectin polypeptide at the site where the collectin's CRD was  
5 purposefully removed.

2. introducing into the host cell, a second DNA construct including a transcriptional promoter operably linked to a second secretory signal sequence followed downstream by, and in proper reading frame with, a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand, joined to a  
10 fourth DNA sequence encoding a collectin polypeptide, wherein the collectin's CRD was purposefully removed, and then,

3. growing the host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein the first polypeptide chain of a TNFSF-SPD  
15 protein is bound by parallel bonding of the respective collectin domain trimer to the second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein the multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs, and

4. isolating the biologically active, multimerized TNFSF-SPD polypeptide  
20 fusion from said host cell. The chimeric reactant compounds are humanized to guard against destruction by a potential human recipient's immune system.

A final method of preparing a multimeric TNFSF-SPD ligand fusion protein contemplated requires a) preparing a first DNA segment coding for a  
25 strand of an exposed extracellular portion of TNFSF; b) preparing a second DNA segment coding for a collectin polypeptide strand, wherein the collectin's CRD domain of the strand has been removed; c) conjoining the first and second DNAs in proper reading frame, thereby creating a TNFSF-collectin DNA construct; d) inserting the construct into an expression vector system; e) introducing the vector

system into an appropriate cell in culture under suitable conditions; f) harvesting and purifying spent medium from the culture; and finally g) assaying for presence of multimeric TNFSF-collectin fusion protein.

5           A method for stimulating the immune response in potentially immunocompetent cells using multimeric TNFSF fusion proteins by contacting the cells with the multimeric TNFSF fusion proteins, causing the cells to proliferate, is also contemplated. The cells used may be resting B cells. There is also a method for increasing antigenicity of cells by contacting the cells with the  
10           multimeric TNFSF fusion proteins. In this case, the cells may be tumor cells or HIV positive cells.

Other preferred embodiments contemplate the methods of preparation described above, wherein the host transformed is either a prokaryote, such as E. coli,  
15           a eukaryote, for example yeast, such as S. cerevisiae, or a higher plant, such as alfalfa or tobacco.

Still further embodiments and advantages of the invention will become apparent to those skilled in the art upon reading the entire disclosure contained  
20           herein.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1. Structure of the CD40L-SPD fusion protein.** The extracellular  
25           portion of the CD40L homotrimer, including its membrane-proximal stalk, was fused to the body of SPD. The N-terminus of SPD contains two cysteines which link the homopolymer together by disulfide bonds forming a hub. The trimeric collagenous stalk extend from the hub as a cruciate structure and end in a spontaneously trimerizing neck region. The amino acid domains in a single chain

of the CD40L-SPD are shown at the top. At the bottom is the tetrameric (four CD40L trimers) which is expected to form. In addition, the hub region of SPD can participate in stacking up to 8 or more cruciate forms into higher order aggregates.

5

**Figure 2. Ion-exchange chromatography of murine CD40L-SPD.** CHO cells expressing murine CD40L-SPD were grown in serum-free media, concentrated using a 100 kDa cutoff ultrafiltration membrane, and diafiltered into 50 mM bicine, pH 9.0, 1 mM EDTA. Using an FPLC system, the protein from 400 mL of media was applied to a Fractogel SO<sub>3</sub><sup>-</sup> 650M column and eluted with a linear salt gradient. 3 mL samples were collected. Shown are curves for protein concentration (OD<sub>280</sub>), conductivity as % 1 M NaCl in the buffer, and ELISA-detectable CD40L-SPD assayed at 1:100 dilution.

15 **Figure 3. Size fractionation of murine CD40L-SPD by ultrafiltration.**

CD40L-SPD is a 471 amino acid protein with a predicted molecular weight of 49,012 for each of the twelve component chains in the dodecamer (composed of four trimeric subunits). This does not include added carbohydrates. Therefore, the full dodecamer will have a molecular weight in excess of 600,000. However, from the literature on recombinant surfactant protein D made in CHO cells, it appears that some of the product will be in the form of trimers that are not part of a cruciate-formed dodecamer. To determine what percentage of CD40L-SPD was produced in a multimeric form, supernatant from the transfected CHO cells were passed through filters of different porosities (rated for their ability to retard globular proteins). An ELISA was used to detect the amount of CD40L-SPD (measured at multiple dilutions) that passed through the filter. As shown, about 90% of the protein is retained by a 300,000 kDa cut-off filter. This indicates that most of the protein is in the dodecameric form. In addition, the cruciate dodecamers of surfactant protein D can also stack on top of each other into even

higher molecular weight forms. This is the likely explanation for the small fraction of CD40L-SPD that is retained by the 1,000 kDa cut-off filter.

**Figure 4. Activation of human B cells by human CD40L-SPD.** Conditioned media from CHO cells expressing human CD40L-SPD was added to human B cells along with IL-4. In the left panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD3 to identify T cells. As shown, most of the cells proliferating in the culture were CD19<sup>+</sup> CD3<sup>-</sup> B cells. In the right panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD80 (B7-1) to identify this co-stimulatory molecule. As shown, almost all of the B cells were induced by CD40L-SPD to express CD80.

**Figure 5. Activation of murine B cells by murine CD40L-SPD.** Murine CD40L-SPD was added to resting murine splenic B cells for a two day culture period. For the final 4 hours, the cultures were pulsed with <sup>3</sup>H-thymidine, following which the cells were harvested and DNA synthesis was measured by scintillation counting. As shown, CD40L-SPD is nearly as effective as anti-IgM in promoting the proliferation of resting B cells.

20

**Figure 6. CD40L-SPD stimulation of macrophage chemokine production.** Conditioned media from CHO cells expressing human CD40L-SPD, an inactive mutant of human CD40L-SPD (T147N-CD40L-SPD), or murine CD40L-SPD (mCD40L-SPD) were added to cultures of human monocyte-derived macrophages. As a negative control, this media was heat-inactivated at 60 °C for 30 minutes. Also shown is a form of soluble CD40L (sCD40L) consisting of 149 amino acids from the extracellular domain of human CD40L (Peprtech) added at 1 µg/mL. 24 hours later, supernatants were collected and assay for MIP-1α by ELISA (R & D Systems). The weak activity of soluble single-trimer CD40L

(sCD40L) is apparent. In contrast, native human and murine CD40L-SPD strongly activated the macrophages to produce MIP-1 $\alpha$ . In contrast, heat-inactivated CD40L-SPD was inactive. As expected, the inactive mutant, T147N-CD40L-SPD, also failed to stimulate macrophages, demonstrating that the CD40L  
5 portion and not the SPD portion of the protein was responsible for stimulating the macrophages.

**Figure 7. Expression of RANKL/TRANCE-SPD production from CHO cells detected by ELISA.** Antibodies against RANKL/TRANCE were used to  
10 construct an ELISA capable of detecting the RANKL/TRANCE protein. As shown, there was no background with the media control. Using a fusion protein between CD70 (CD27L or TNFSF7) and SPD, there was also no signal, indicating the specificity of the ELISA. However, using CHO cells transfected with an expression plasmid for CD70-SPD, immunoreactive secreted protein was clearly  
15 detectable. This demonstrates the generalizability of the method for expressing TNFSF members as fusion proteins with collectins such as SPD.

## DESCRIPTION OF THE PREFERRED EMBODIMENT

### 1. Definition of Terms

20 **Multimeric:** As used herein the term multimeric refers to a multimer of a polypeptide that is itself a trimer (i.e., a plurality of trimers).

**Functional Equivalent:** Herein refers to a sequence of a peptide or polypeptide that has substantial structural similarity and functional similarity to another such sequence.

25 **Modifications:** Herein refers to point changes involving single amino acids, wherein the functionality is altered, without appreciably altering the primary sequence or primary structure of a peptide or polypeptide.

**Amino Acid:** All amino acid residues identified herein are in the natural L-configuration. In keeping with standard polypeptide nomenclature, J. Biol.

Chem., 243:3557-59, (1969), abbreviations for amino acid residues are as shown in the following Table of Correspondence:

5

## TABLE OF CORRESPONDENCE

10	<u>SYMBOL</u>		<u>AMINO ACID</u>
	<u>1-Letter</u>	<u>3-Letter</u>	
	Y	Tyr	L-tyrosine
	G	Gly	glycine
15	F	Phe	L-phenylalanine
	M	Met	L-methionine
	A	Ala	L-alanine
	S	Ser	L-serine
	L	Ile	L-isoleucine
20	L	Leu	L-leucine
	T	Thr	L-threonine
	V	Val	L-valine
	P	Pro	L-proline
	K	Lys	L-lysine
25	H	His	L-histidine
	Q	Gln	L-glutamine
	E	Glu	L-glutamic acid
	W	Trp	L-tryptophan
	R	Arg	L-arginine
30	D	Asp	L-aspartic acid
	N	Asn	L-asparagin
	C	Cys	L-cysteine

It should be noted that all amino acid residue sequences are represented herein by  
 35 formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a radical such as H and OH (hydrogen and hydroxyl) at the amino- and carboxy-termini, respectively, or a further sequence of one or more amino acid residues up to a

total of about fifty residues in the polypeptide chain.

**Base Pair (bp):** A partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.

**Constitutive promoter:** A promoter where the rate of RNA polymerase  
5 binding and initiation is approximately constant and relatively independent of external stimuli. Examples of constitutive promoters include the cauliflower mosaic virus 35S and 19S promoters described by Poszkowski et al., *EMBO J.*, 3:2719 (1989) and Odell et al., *Nature*, 313:810 (1985).

**DNA:** Desoxyribonucleic acid.

10 **Enzyme:** A protein, polypeptide, peptide RNA molecule, or multimeric protein capable of accelerating or producing by catalytic action some change in a substrate for which it is often specific.

**Expression vector:** A DNA sequence that forms control elements that regulate expression of structural genes when operatively linked to those genes.

15 **Expression:** The combination of intracellular processes, including transcription and translation undergone by a structural gene to produce a polypeptide.

**Insert:** A DNA sequence foreign to the rDNA, consisting of a structural gene and optionally additional DNA sequences.

20 **Nucleotide:** A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleoside. When the nucleoside contains a phosphate group bonded to the 3' or 5' position of the pentose it is referred to as  
25 a nucleotide.

**Operatively linked or inserted:** A structural gene is covalently bonded in correct reading frame to another DNA (or RNA as appropriate) segment, such as to an expression vector so that the structural gene is under the control of the expression vector.



**Polypeptide and peptide:** A linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

**Promoter:** A recognition site on a DNA sequence or group of DNA  
5 sequences that provide an expression control element for a gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene.

**Inducible promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include light,  
10 heat, anaerobic stress, alteration in nutrient conditions, presence or absence of a metabolite, presence of a ligand, microbial attack, wounding and the like.

**Spatially regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism such as the leaf, stem or root. Examples of spatially regulated  
15 promoters are given in Chua et al., *Science*, 244:174-181 (1989).

**Spatiotemporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism at a specific time during development. A typical spatiotemporally regulated promoter is the EPSP synthase-35S promoter described by Chua et al.,  
20 *Science*, 244:174-181 (1989).

**Temporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated at a specific time during development. Examples of temporally regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

25 **Protein:** A linear series of greater than about 50 amino acid residues connected one to the other as in a polypeptide.

**Recombinant DNA molecule:** A hybrid DNA sequence comprising at least two nucleotide sequences not normally found together in nature.

**RNA:** Ribonucleic acid.

**Selective Genetic marker:** A DNA sequence coding for a phenotypical trait by means of which transformed cells can be selected from untransformed cells.

**Structural gene:** A DNA sequence that is expressed as a polypeptide, i.e.,  
5 an amino acid residue sequence.

**Synthetic promoter:** A promoter that was chemically synthesized rather than biologically derived. Usually synthetic promoters incorporate sequence changes that optimize the efficiency of RNA polymerase initiation.

## 10 2. Introduction

This invention discloses the production of TNFSF proteins as multimeric (i.e., many trimers) ligands fused onto a trimeric, branched protein backbone. Collectin molecules are ideal for this purpose because they are formed from many trimeric, collagenous arms linked to a central hub by disulfide bonds. Of the  
15 collectins, pulmonary surfactant protein D (SPD) was chosen initially because it is a homopolymer encoded by a single gene, unlike C1q and surfactant protein A, which are composed of two different protein subunits. In addition, recombinant SPD has been successfully expressed *in vitro* in reasonable yield [Crouch, 1994], and a peptide containing the "neck" region of SPD was shown to spontaneously  
20 trimerize in solution [Hoppe, 1994]. Consequently, extracellular domains of human and murine CD40L were substituted for the carbohydrate recognition domain of pulmonary surfactant D (SPD) to create a four-armed molecule (three peptide chains per arm) with CD40L at the end of each arm. This molecule is named CD40L-SPD. In addition, because SPD tends to stack into higher order  
25 aggregates with up to 8 molecules associated at the hub [Crouch], even greater degree of multimerization can occur [Lu, 1993]. CD40L-SPD therefore mimics the expression of CD40L by an activated T cell in that it presents a multivalent complex similar to membrane-bound CD40L. While remaining soluble, CD40L-SPD equals membrane CD40L in its range of activities.

### 3. Construction of expression plasmids for CD40L-SPD.

cDNAs of exposed human and murine CD40L, removed from cell membranes, were cloned by PCR by well-known methods. Murine surfactant protein D was cloned by hemi-nested PCR from murine lung mRNA (Clontech).

- 5 cDNA was prepared using Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD) and random hexamers as primers. PCR primer sequences were as follows (the underlined bases indicate restriction endonuclease sites for cloning into the vector):

10 mSPD5: 5'-CTGACATGCTGCCCTTTCTCTCCATGC-3'  
 mSPD3ext: 5'-GGAGGCCAGCTGTCCTCCAGCCTGTTTGC-3'  
 rmSPD5: 5'-GGGGCTAGCGAATTCACCAGGAAGCAATCTGACATGCTGCCCTTTCTCT  
 CCATGC-3'  
 CD40L/SPD3: 5'-CTATCTTGTCCTCAACCTTCTATG/GCCATCAGGGAACAATGCAGCTTTC-3'  
 15 SPD/CD40L5: 5'-AAAGCTGCATTGTTCCCTGATGGC/CATAGAAGGTTGGACA AGATAGAAG-3'  
 CD40L3: 5'-GGGCTCGAGGTACCAGTTCTACATGCCTTGGAGTGTATAAT-3'  
 SPD/mCD40L5: 5'-GAAAGCTGCATTGTTCCCTGATGGC/CATAGAAGATTGGATAAGGTCGAAG-3'  
 mCD40L/SPD3: 5'-CTTCGACCTTATCCAATCTTCTATG/GCCATCAGGGAACAATGCAGCTTTC-3'  
 mCD40L3: 5'-GGGGGGTACCCTGCTGCAGCCTAGGACAGCGCAC-3'

- 20 Because the murine SPD sequence of the 5' untranslated region containing the ribosomal binding site was unknown when this work was started [Motwani, 1995], a primer (rmSPD5) was designed based on the available rat sequence [Shimizu, 1992] which extended the 5' end with rat sequence (shown in bold) along with an added Nhe I site (underlined).

25

### 4. Creation of the CD40L-SPD Fusions.

To create the CD40L-SPD fusions, overlap PCR was used. Murine SPD was amplified by nested PCR using mSPD5 and mSPD3ext for the first round of 30 cycles. The product was diluted 1:1,000 and 1  $\mu$ L was amplified for another

30 cycles using rmSPD5 and CD40L/SPD3, where the 3' half of CD40L/SPD3 is a reverse primer for SPD C-terminal to the neck region (deleting the CRD) and the 5' half of CD40L/SPD3 contains bases from the N-terminus of the extracellular portion of CD40L (immediately adjacent to the transmembrane region). Similarly, the CD40L plasmid was amplified with SPD/CD40L5 and CD40L3, which contains a Kpn I site (underlined). All of these PCRs were performed with Pfu cloned polymerase (Stratagene,) using hot start (Ampliwax, Perkin-Elmer) and the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 43 °C for 30 sec, and 75 °C for 7 min.

10

To form the chimeric construct, 1 µL of a 1:1,000 dilution of gel-purified products from the above reactions was combined and amplified with rmSPD5 and CD40L3. Because Pfu polymerase did not consistently yield the expected 1.62 kb overlap product, AccuTaq LA DNA polymerase (Sigma) was used for this PCR, using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 98 °C for 20 sec, 43 °C for 30 sec, and 68 °C for 10 min. The resulting product was digested with Nhe I and Kpn I, gel-purified, and ligated into the Nhe I and Kpn I sites in the expression plasmid, pcDNA3.1(+) (Invitrogen, Carlsbad, CA). DH5 E. coli were transformed with the construct and plasmid DNA was purified either by double banding in ethidium bromide-CsCl gradients or by anion exchange resin (QIAGEN). To form the T147N-CD40L-SPD construct, the same approach was used except that the CD40L coding region was taken from the expression plasmid for T147N-CD40L [Kornbluth]. The amino acid sequence at the junction between SPD and CD40L is ...KAALFPDG/HRRLDKIE..., where the C-terminal portion begins the sequence for CD40L. To form mCD40L-SPD, a similar approach was taken except that primers SPD/mCD40L5, mCD40L/SPD3, and mCD40L3 were used for amplifications involving murine CD40L sequences. The amino acid sequence at the junction between SPD and murine CD40L is ...KAALFPDG/HRRLDKVE..., where the C-terminal portion begins the sequence

15  
20  
25

for murine CD40L. Both DNA strands of each construct were sequenced to confirm that the constructs were correct. In other experiments, an entirely humanized construct, consisting of human CD40L fused to human SPD, was constructed (data not shown).

5

#### 5. Construction of expression plasmid for murine RANKL/TRANCE (TNFSF 11).

Spleen cells from C3H/HeJ mice were stimulated with 5  $\mu$ g/ml concanavalin A and 10 ng/ml IL-2 (Sigma) for 8 hours (31). mRNA was isolated using the Micro FastTrack kit (Invitrogen). cDNA was prepared using Superscript II reverse transcriptase (Life Technologies) and random hexamers as primers. PCR primer sequences were as follows (where the underlined bases indicate restriction endonuclease sites for cloning into the vector):

5mRANKL-ext:	5'-CATGTTCTGCGCCCTCCTC-3'
15 3mRANKL-ext:	5'-GTACAGGCTCAAGAGAGAGGGC-3'
5mRANKL-int:	5'-ATACTCGAGCGCAGATGGATCCTAAC-3'
3mRANKL-int:	5'-GGGGTTTAGCGGCCGCTAATGTTCCACGAAATGAGTTC-3'

The extracellular portion of RANKL/TRANCE was cloned by nested PCR. In the first round of PCR, 5mRANKL-ext and 3mRANKL-ext were used with Pfu cloned polymerase (Stragene) using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 50 °C for 30 sec, and 75 °C for 2 min. The product was diluted 1:1,000 and 1  $\mu$ L was amplified for another 30 cycles using 5mRANKL-int and 3mRANK-int, which contain an Xho I site and a Not I site respectively. The resulting product was digested with Xho I, blunt-ended with T4 DNA polymerase, then digested with Not I and gel-purified. The CD40L-SPD expression plasmid described above was digested with Msc I and Not I and gel purified. Then the RANKL/TRANCE sequence was ligated into this vector in frame with the SPD coding sequence. The amino acid sequence at

the junction between SPD and RANKL/TRANCE is

...KAALFPDG/RAQMDPNR..., where the N-terminal portion is from SPD and the C-terminal portion is the extracellular sequence of RANKL/TRANCE. Both DNA strands of each construct were sequenced to confirm that the constructs

5 were correct.

6. **Stable transfection of DHFR-deficient CHO cells and amplification.**

DG44 (a line of CHO-K1 cells deficient in dihydrofolate reductase (DHFR)) (32) and pCH1P (a plasmid containing the hamster DHFR minigene) (33) were gifts from Dr. Lawrence Chasin, Columbia University, New York, NY. DG44 cells were cultured in 10  $\alpha$ -MEM consisting of ribo- and deoxynucleoside-free  $\alpha$ -MEM (BioWhittaker, Walkersville, MD) supplemented with 200  $\mu$ M L-glutamine, 10% fetal bovine serum (FBS) and 10  $\mu$ g/ml each of adenosine, deoxyadenosine, and thymidine (Sigma). All cell cultures described were negative in a mycoplasma rRNA assay (Gen-Probe, San 15 Diego). DG44 cells in six-well plates were transfected by the method of Okayama and Chen ((34) with 10  $\mu$ g of expression plasmid and 0.05  $\mu$ g of pCH1P (200:1 ratio). After two days, the transfected DG44 were trypsinized and transferred to 100 mm plates. At this point, the media was switched to  $\alpha$ -MEM which differs from  $\alpha$ -MEM in that dialyzed FBS (HyClone Systems, Logan, UT) was used and no nucleoside supplements 20 were added. Only cells containing the DHFR minigene were able to grow in  $\alpha$ -MEM, and colonies were selected after 10 days, cloned using cloning rings, and transferred to 12.5 cm<sup>2</sup> flasks. Clones were selected for expansion using an ELISA to screen for the production of either murine or human CD40L (see below). Using the method described by Kingston *et al.* (35), escalating doses of methotrexate were used to amplify the 25 transfected genes over a period of 6-14 months until the cells grew well in 80  $\mu$ M methotrexate. Each expressing clone was re-cloned once or twice more in order to select the highest expressing cells.

7. **Preparation of human and murine CD40L-SPD in serum-free media.**

30 Selected clones were adapted for growth in nucleoside-free UltraCHO media (BioWhittaker) supplemented with 50-100  $\mu$ g/mL ascorbic acid and 50  $\mu$ M

methotrexate (Sigma). The non-adherent population was further adapted for suspension growth in roller bottles. In some experiments, the cells were adapted from  $\alpha$ -MEM to CHO-S-SFM II media (Life Technologies) supplemented with ascorbic acid and 50  $\mu$ g/mL L-proline.

5

8. **ELISA assay for human and murine CD40L-SPD.**

To assay for correctly folded CD40L, wells of a MaxiSorb 96-well plate (Nunc) were coated overnight at 4 °C with 50  $\mu$ L of carbonate-bicarbonate, pH 9.40 buffer containing 0.5  $\mu$ g/mL 24-31 anti-human CD40L MAb (Ancell) or  
10 MR1 anti-murine MAb (Bioexpress, Lebanon, NH). Wells were blocked with 3% bovine serum albumin (BSA) in PBS. 100  $\mu$ L samples were added to the wells either neat or diluted in a dilution buffer consisting of 1% BSA, 0.9 % NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20 (Sigma). After shaking for 2 h at 600 RPM, a plate washer was used to wash the plate four times with 0.9 %  
15 NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20. Then, 100  $\mu$ L of diluent buffer containing 1  $\mu$ g/mL biotinylated 24-31 anti-human CD40L Mab (Ancell) or MR1 anti-murine CD40L Mab (Pharmingen, San Diego, CA) was added to each well and again shaken for 2 h. Following another four washes, 100  $\mu$ L of diluent buffer containing 1  $\mu$ g/mL of streptavidin-alkaline phosphatase  
20 (Jackson) was added to each well and the plate was shaken for 1 hour. Lastly, after another four washes, color was developed for 10-20 min using 100  $\mu$ L/well of BluePhos (Kierkegaard & Perry), stop solution was added, and the wells were read at 650  $\mu$ m in a plate reader.

25 9. **Purification of human and murine CD40L-SPD.**

Conditioned UltraCHO media was filtered using a 0.2  $\mu$  PES filter unit (Nalgene) and stored at 4 °C for up to 3 months. A preliminary size fractionation was performed by ultrafiltration through a 100 kDa-cutoff 76 mm membrane (YM-100, Millipore) in a 400 mL stirred cell at 10 lbs/sq. inch pressure of argon.

Media was concentrated to about 10 mL, diluted to 100 mL with buffer, and again concentrated to 10 mL for a total of 3 cycles of ultrafiltration and buffer exchange. Buffer was 50 mM Bicine (Calbiochem), adjusted to pH 9.0 with NaOH (about 32 mM Na), and 1 mM EDTA to prevent the activity of any metalloproteinase. Using FPLC equipment (Amersham-Pharmacia), the concentrate was filtered through a 0.45  $\mu$  filter, placed into a 10 mL superloop, applied to a 10 X 30 mm column (HR10/30, Amersham-Pharmacia) packed with Fractogel SO<sub>3</sub><sup>-</sup> 650M (EM Biosciences), and eluted at 0.5 mL/min at 4 °C with a linear gradient of 0-500 mM NaCl in buffer. As described by the manufacturer, the resolution of proteins on Fractogel SO<sub>3</sub><sup>-</sup> is enhanced by using a long, thin column geometry. Fractions were collected and screened for human or murine CD40L by ELISA. Positive fractions were pooled, concentrated by ultrafiltration (CentriPrep-30, Millipore), filtered through a 0.45  $\mu$  filter, and applied to a Superose 6 column (Amersham-Pharmacia) in phosphate-buffered saline.

15

#### 10. Murine B cell cultures.

C3H/HeJ mice were euthanized by CO<sub>2</sub> inhalation under a protocol approved by the Animal Subjects Committee of the San Diego VA Healthcare System. Splenocytes were isolated by centrifugation over Lympholyte-M (Accurate Chemical & Scientific Corp., Westbury, NY) and B cells were isolated by negative selection using anti-CD43 immunomagnetic beads (Milenyi Biotec Inc., Auburn, CA). The resting B cells were suspended in Dulbecco's MEM with 10% FBS at a concentration of  $1 \times 10^6$ /mL, and 100  $\mu$ L was added to the wells of 96-well flat-bottomed plates. 100  $\mu$ L of dilutions of murine CD40L-SPD in media or media alone were added to the wells, which were incubated in 8.5% CO<sub>2</sub> at 37 °C for 48 hours. Then, 0.5  $\mu$ Ci/well of <sup>3</sup>H-thymidine was added to each well, and the cells were collected 4 h later onto glass fiber filters using an automated cell harvester. A scintillation counter was used to determine the incorporated radioactivity.



**11. Human B cell cultures.**

Venous blood from consenting subjects was used as a source of human B cells under a protocol approved by the UCSD Institutional Review Board. Blood was collected into syringes containing 5 U/mL heparin and peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll-hypaque. The cells were suspended at  $2 \times 10^5$ /mL in RPMI 1640 containing 200  $\mu$ M L-glutamine, 10% FBS, 0.832  $\mu$ M cyclosporin A (Sigma), and 25 ng/mL human IL-4 (R & D Systems) and incubated in 5% CO<sub>2</sub> at 37 °C as described by Schultze *et al.* (36). At intervals, the cells were stained with CyChrome-conjugated anti-CD19 and PE-conjugated anti-CD80 (B7-1) monoclonal antibodies (Pharmingen) and analyzed by flow cytometry.

**12. Human monocyte-derived macrophage and dendritic cell cultures.**

As previously described [Kornbluth], monocytes were isolated from PBMC by adherence to fibronectin-coated plates, plated into 48-well plates, and then cultured in RPMI1640 containing 200  $\mu$ M L-glutamine and 10% autologous serum for 7-10 days. Monolayers of the matured cells (about  $2 \times 10^5$ /well), termed monocyte-derived macrophages or MDM, were then washed in media and cultured in 1 mL/well RPMI1640 containing 200  $\mu$ M L-glutamine and 10% heat-inactivated FBS. Alternatively, dendritic cells (DC) were formed from monocytes by adding GM-CSF and IL-4 to the culture media, and the resulting DC were used 6 days later. Preparations of CD40L-SPD were added to the wells as indicated. As a positive control, 100 ng/mL bacterial lipopolysaccharide (LPS) from E. coli 0111:B4 (Calbiochem) was added. Supernatants were collected 24 h later and analyzed for cytokine content using ELISA (R & D Systems).

**Example 1.****Design principles in constructing collectin-TNFSF member fusion proteins.**

To express CD40L and other TNFSF members as stable, multimeric

proteins, the coding region of the extracellular, C-terminal portion of CD40L was joined in-frame to the collectin, surfactant protein D (SPD). The N-terminus of SPD contains two cysteines which form the disulfide bonds necessary for the 4-armed cruciate structure of the overall molecule [Brown-Augsburger, 1996 #506].

5 C-terminal to these cysteines in SPD is a long triple-helical collagenous "stalk" which ends in the "neck" region that promotes the trimerization of each arm of the structure. Immediately after this neck region, the coding sequence for the extracellular portion of CD40L was added, in place of the carbohydrate recognition domain (CRD) of SPD. The collectins were chosen as the framework

10 for the multimeric construct because of their multi-subunit structure and the trimeric nature of their stalk regions. Appropriateness of replacing the CRD of a collectin with the extracellular region of a TNFSF member is further supported by structural studies of the two protein families. An analysis of the CRD crystal structure of another collectin, ACRP30, indicated that it was structurally

15 superimposable upon the crystal structures of the extracellular regions of CD40L, TNF, and Fas [Shapiro, 1998]. The successful expression of the collectin-TNFSF fusion protein, CD40L-SPD, indicates that other TNFSF members (Table I) could be conjoined to SPD in a similar manner and that other collectins besides SPD (Table II) could be used as a protein framework instead of SPD. Because these

20 molecules are formed entirely from naturally occurring proteins, the production of an immune response (e.g., antibodies) to these fusion proteins is minimized. By deleting portions of the stalk region of the TNFSF proteins, additional constructs can be made which may be even less immunogenic.

## 25 **Example 2.**

### **Expression of human and murine CD40L-SPD in CHO cells.**

The coding regions for the extracellular portion of human CD40L, human T147N-CD40L, an inactive mutant of CD40L, or murine CD40L were joined to the neck region of murine SPD, replacing the SPD CRD (Fig. 1). A CMV-driven

expression plasmid for the construct was co-transfected with a DHFR minigene into DNFR-deficient CHO cells. Following selection in nucleoside-free media, expressing CHO clones were amplified by culture in ascending doses of methotrexate. The resulting clones produced about 1-10 µg/mL of the fusion  
5 protein over a 3 day period in media containing FBS.

Clones were adapted for growth as suspension cells in two types of serum-free media. Murine CHO-SPD produced in UltraCHO (BioWhittaker) was largely retained (about 60% as determined by ELISA) by a 1,000 kDa cutoff  
10 ultrafiltration membrane (Pall Corp., Port Washington, NY), consistent with a large multimeric complex formed by the stacking of the SPD portion of the molecule. However, in CHO-S-SFM II (Life Technologies), nearly all ELISA-detectable murine CHO-SPD passed through a 100 kDa cutoff ultrafiltration membrane (Millipore), suggesting that the protein was either folding incorrectly  
15 in this media or was being degraded by proteolysis. Consequently, the purification method was optimized for the spent UltraCHO media.

### **Example 3.**

#### **Purification of human and murine CD40L-SPD.**

20 Purification procedures were developed for murine CD40L-SPD, but the same methods could be applied to human CD40L-SPD with minor modifications. Murine CD40L-SPD has a predicted m.w. of 49 kDa per chain, or about 600 kDa per 12-chain, cruciate molecule, the amino acid sequence predicts a pI of 9.10. Accordingly, conditioned media was concentrated by ultrafiltration through a 100  
25 kDa cutoff filter, which also fractionates the sample on a size basis. After diafiltration into 50 mM bicine, pH 9.00 (also containing 1 mM EDTA added to inhibit metalloproteinases), the sample was applied to a variety of cationic exchange resins. Using Source 30S (Amersham-Pharmacia), most of the ELISA-detectable protein did not bind and was recovered in the flow-through. However,

as reported by Morris et al. {Morris}, Fractogel SO<sub>3</sub> 650M retained the protein. The retention by this tentacular resin and not by Source 30S suggests binding to positively charged residues that are not on the protein surface. Using a linear NaCl gradient, ELISA-detectable protein elutes at between 0.15-0.30 M NaCl under these conditions (Fig. 2). In selected experiments, the protein was further purified using a Superose 6 sizing column. Most of the ELISA-detectable protein eluted in the excluded volume, indicating an apparent m.w. of greater than 1,000 kDa (Fig. 3).

#### 10 **Example 4.**

##### **Activity of CD40L-SPD on human B cells.**

Schultze *et al.* described a system using CD40L-expressing cells plus IL-4 and cyclosporin A (to inhibit T cell growth) as a means to grow very large numbers of B cells from a small sample of blood. Because CD40L activates these B cells to express high levels of B7 molecules (CD80 and CD86), the proliferating B cells were effective in presenting peptide antigens and rival non-dividing dendritic cells as antigen-presenting cells (APCs) (36). To determine if the CD40L-SPD fusion protein could replace CD40L-expressing cells in this system, PBMC were cultured with CD40L-SPD in addition to IL-4 and cyclosporin A. Under these conditions the cells grew to saturation density every three days. After three weeks, the cultures were almost entirely CD19+ B cells which express high levels of CD80 (Fig. 4). This indicates that CD40L-SPD can be used in *ex vivo* systems where a soluble yet effective form of CD40L is needed to stimulate cells for immunotherapeutic applications.

25

#### **Example 5.**

##### **Activity of CD40L-SPD on murine B cells.**

Resting murine B cells are particularly difficult to stimulate with most soluble forms of CD40L. Even with murine CD40L-CD8 fusion proteins, it is

necessary to crosslink the protein with antibodies against CD8 in order to achieve maximal proliferation in culture [Klauss, 1999]. Accordingly, resting murine B cells were negatively selected with immunomagnetic beads. As shown in Fig. 5, murine CD40L-SPD was as effective as anti-IgM antibody in driving B cells to  
5 proliferate. This indicates that CD40L-SPD can mimic the multivalent interactions that occur when a responding cell comes in contact with CD40L-bearing activating cells.

#### **Example 6.**

##### **10 Activity of CD40L-SPD on human macrophages and dendritic cells.**

CD40L is a powerful stimulant for macrophages (reviewed in (28)) and dendritic cells (40). Accordingly, preparations of CD40L-SPD were added to monocyte-derived macrophages and the production of MIP-1 $\alpha$  was used as a measure of stimulation. As shown in Fig. 6, both human and murine CD40L-SPD  
15 were able to stimulate macrophages, whereas the T147N-CD40L-SPD mutant was inactive as expected.

## **DISCUSSION**

These examples define a new method of producing multimeric (i.e., many  
20 trimers) of CD40L as a fusion protein with SPD. Also prepared and expressed were similar fusion proteins between murine RANKL/TRANSE (TNFSF11) or murine CD27L/CD70 (TNFSF7) joined to murine SPD (data not shown). This suggests that virtually all TNFSF members could be successfully produced as fusion proteins with SPD. Furthermore, it is also likely that other collectins  
25 besides SPD could be used in these fusions, given the strong structural homologies between the CRDs of the collectins and the extracellular domains of TNFSF members [Shapiro] which can be substituted for these CRDs. Given the 17 known TNFSF members and 9 known collectins, at least 153 fusion protein combinations are possible.

SPD was selected for initially because it is a soluble homopolymer. Other collectins, such as surfactant protein A, have strong binding affinities to lipids and specific cell receptors. Although removal of the CRD abrogates much of this binding, it may be partially mediated by the neck region sequence, which the fusion proteins retain. Accordingly, it would be expected that collectins other than SPD might confer different cell-binding and pharmacokinetic behaviors upon a fusion protein. For example, macrophages are known to take up and degrade whole SPD [Dong, 1998]. If a fusion protein other than SPD were used, the disposition of the fusion protein *in vivo* might be altered. Additionally, metalloproteinases are known to degrade the collectin, C1q, so that a fusion with C1q may alter the degradation of the fusion protein. For example, because CD40L activates macrophages and other cells to produce metalloproteinases, which could potentially degrade the collagenous portion of SPD and other collectins. Cleavage of the collagenous stalk would then be expected to release single-trimers of CD40L, which could diffuse away from the original parent molecule, much like a slow-release formulation of a drug. Also, the membrane-proximal portion of CD40L has been retained in CD40L-SPD. This sequence also contains protease-susceptible amino acid sequences, which can be eliminated by mutagenesis to retard the cleavage of CD40L from the fusion protein. Mutations in such proteinase cleavage site(s) would delay such cleavage and favor the local persistence of the CD40L stimulus.

CD40L-SPD is a large macromolecule (> 1,000 kDa), and the other TNFSF-collectin fusion proteins would be expected to be similarly large. For native SPD, the aggregates that spontaneously form measure 100 nm in diameter. When injected into tissue, this large a complex would be expected to remain at the injection site for a prolonged period. Localization of the TNFSF-containing protein would also be expected to reduce any systemic toxicity caused by the release of free single-trimers into the circulation. For example, soluble CD40L in

blood has been linked to disease activity in lupus, and this smaller molecule may even cross the glomerulus to cause damage to renal tubules [Kato and Kipps, J. Clin. Invest. Nov. 1999]. On the other hand, because CD40L induces the production of chemokines which attract immune cells [Kornbluth], T cells, monocytes, and dendritic cells would be expected migrate to the site where CD40L-SPD was injected. This might be advantageous if CD40L-SPD were used as a vaccine adjuvant. In mice, soluble CD40L (sCD40LT) stimulates IgG1 production but not cytotoxic T lymphocytes (CTLs) [Wong, 1999]. Interestingly, the same protein that is expressed from an injected plasmid stimulates both a strong antibody and CTL response [Gurunathan, 1998]. In the latter case, the plasmid would be expected to deliver a localized supply of CD40L, whereas the sCD40LT protein is free to diffuse away. Support for the localized use of CD40L in an adjuvant formulation is provided by a study using a plasmid expressing full-length membrane CD40L, which was very effective in stimulating both humoral and CTL immune responses [Mendoza, 1997]. Similarly, injection of adenovirus expressing membrane CD40L has potent antitumor activity in mice [Kikuchi, 1999]. Similar considerations would likely apply to other fusion proteins between the TNFSF and collectins.

Finally, for immunostimulatory proteins, it is particularly important that the protein not be antigenic if repeated injections are needed. For example, vaccination with TNF- $\mu$  modified by the addition of short peptide sequences was able to induce the production of disease-modifying anti-TNF- $\mu$  autoantibodies [Dalum, 1999]. Because CD40L-SPD and other TNFSF-collectin fusion proteins are formed from endogenous protein sequences (with the possible exception of the peptide sequence at the junction), the production of antibodies might not limit the effectiveness of repeated injections.

In conclusion, fusions between TNFSF members and collectins offer a

novel means of generating large protein complexes which can provide localized stimulation at an injection site. Because of the multimeric nature of the collectin backbone, such fusion proteins may mimic the multivalent ligand surface presented by the membrane forms of TNFSF members to TNFRSF-bearing  
5 responding cells. Moreover, by limiting systemic toxicity while maintaining localized efficacy, such fusion proteins may have a role as vaccine adjuvants against infectious agents and tumors.



Table I  
**Ligands of the TNF Superfamily\***

<u>New Ligand Symbol</u>	<u>Other Names</u>	
<u>Genbank ID</u>		
LTA	Lymphotoxin-, TNF- $\alpha$ , TNFSF1	X01393
TNF	TNF- $\alpha$ , TNFSF2	X02910
LTB	Lymphotoxin-, TNFSF3	L11016
TNFSF4	OX-40L	D90224
TNFSF5	CD40L, CD154, Gp39, T-BAM	X67878
TNFSF6	FasL	U11821
TNFSF7	CD27L, CD70	L08096
TNFSF8	CD30L	L09753
TNFSF9	4-1BBL	U03398
TNFSF10	TRAIL, Apo-2L	U37518
TNFSF11	RANKL, TRANCE, OPGL, ODF	AF013171
TNFSF12	TWEAK, Apo-3L	AF030099
TNFSF13	APRIL	NM_003808
TNFSF13B	BAFF, THANK, BLYS	AF136293
TNFSF14	LIGHT, HVEM-L	AF036581
TNFSF15	VEGI	AF039390
TNFSF16	unidentified	
TNFSF17	unidentified	
TNFSF18	AITRL, GITRL	AF125303

\*(as of Nov. 1, 1999)

Known members of ligands in the TNF superfamily, taken from the Human

Gene Nomenclature Committee at

<http://www.gene.ucl.ac.uk/users/hester/tnftop.htm>

---

**Table II****The Collectin Superfamily**

C1q	Pulmonary surfactant
Mannose-binding	protein D
protein, MBL1	conglutinin
Mannose-binding	collectin-43
protein, MBL2	CL-L1
Pulmonary surfactant	ACRP30
protein A	Hib27

All collectins are formed as multimers of trimeric subunits, each containing a collagenous domain. The C-terminus of each collectin contains a CRD which binds carbohydrates and other ligands. Because of the tight similarities between  
5 the known CRD structures and the extracellular domains of TNFSF members, it is likely that the CRD of any collectin could be replaced with the extracellular domain of any TNFSF member in a structurally compatible manner.

While the present invention has now been described in terms of certain  
10 preferred embodiments, and exemplified with respect thereto, one skilled in the art will readily appreciate that various modifications, changes, omissions and substitutions may be made without departing from the spirit thereof. It is intended, therefore, that the present invention be limited solely by the scope of the following claims.

15

## CLAIMS

What is claimed is:

- 5        1. A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD fusion protein, said structural gene having a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5.
- 10       2. The DNA segment according to claim 1, wherein the structural gene comprises:
  - a segment expressing a single hybrid amino acid chain of TNFSF-SPD, said segment having
  - 15        a first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and
  - a second sequence, expressing a portion of TNFSF stalk, selected from members of the group consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to base 1528, and SEQ ID NO 5,
  - 20        from base 800 to base 1441.
3. A recombinant DNA molecule comprising a vector operatively linked to an exogenous DNA segment defining a structural gene expressing a single amino acid chain of TNFSF-SPD, said structural gene having
- 25        a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any functional equivalents and modifications thereof, and
- an appropriate promoter for driving the expression of said structural gene in a compatible host organism.

4. The recombinant DNA molecule as described in claim 3 wherein said host organism is *E. coli*.

5 5. The recombinant DNA molecule as described in claim 3, wherein said host organism is a yeast.

6. The recombinant DNA molecule as described in claim 3, wherein said host organism is a higher plant or animal.

10

7. A multimeric TNFSF-SPD fusion protein comprising:  
a plurality of polypeptide trimers,

15

i) a first trimer consisting of peptide strands of members of the TNF superfamily (TNFSF) of ligands, and

ii) a second trimer strand from a collectin molecule

each first trimer conjoined to a second polypeptide trimer strand from a collectin molecule, wherein said ligand strand is substituted for native carbohydrate recognition domains (CRD) of the collectin molecules,

20

said conjoined collectin strands covalently bound in parallel to each other, therein forming a multimeric fusion protein comprising a plurality of trimeric hybrid polypeptide strands radiating from a covalently bound center hub of the molecule, the free end of each trimeric radiating strand having a TNFSF moiety attached.

25

8. The multimeric fusion protein according to claim 6, wherein the TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as in Table II, their functional equivalents, and

modifications thereof.

9. A method for preparing a CD40-SPD multimeric fusion polypeptide, comprising the steps of:

- 5        initiating a culture, in a nutrient medium, of procaryotic or eucaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for said cells, operatively linked to an exogenous DNA segment defining a structural gene for CD40-SPD ligand, said structural gene having a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about  
10    base 1444; and  
      maintaining said culture for a time period sufficient for said cells to express said multimeric molecule.

10. A method of producing a secreted, large, biologically active, multimeric  
15    tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusable, comprising:

- introducing into a host cell a first chimeric DNA construct including  
          a transcriptional promoter operatively linked to a first  
          secretory signal sequence, followed downstream by, and in proper  
20        reading frame with  
          a first DNA sequence encoding a polypeptide chain of  
          a first TNFSF ligand requiring multimerization for biological  
          activity, joined to  
          a second DNA sequence encoding a collectin  
25        polypeptide at the site where the collectin's CRD was  
          purposefully removed,  
      introducing into said host cell a second DNA construct including  
          a transcriptional promoter operably linked to a second  
          secretory signal sequence followed downstream by, and in

proper reading frame with,

a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand , joined to

5 a fourth DNA sequence encoding a collectin polypeptide , wherein the collectin's CRD was purposefully removed;

growing said host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein

10 said first polypeptide chain of a TNFSF-SPD protein is bound by parallel bonding of the respective collectin domain trimer to

said second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein said multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs; and

15 isolating said biologically active, multimerized TNFSF-SPD polypeptide fusion from said host cell.

11. The method according to claim 10, wherein the chimeric reactant compounds are humanized to guard against destruction by a potential human  
20 recipient's immune system.

12. A method of preparing a multimeric TNFSF-SPD ligand fusion protein, comprising:

25 preparing a first DNA segment coding for a strand of an exposed extracellular portion of TNFSF;

preparing a second DNA segment coding for a collectin polypeptide strand, wherein said collectin's CRD domain of the strand has been removed;

conjoining said first and second DNAs in proper reading frame, therein.

- creating a TNFSF-collectin DNA construct;
- inserting said construct into an expression vector system;
- introducing said vector system into an appropriate cell in culture under suitable conditions;
- 5 harvesting and purifying spent medium from said culture; and
- assaying for presence of multimeric TNFSF-collectin fusion protein.

13. A method for stimulating the immune response in potentially immunocompetent cells using multimeric TNFSF fusion proteins, comprising:
- 10 contacting said cells with said multimeric TNFSF fusion proteins, wherein said cells are induced to proliferate.

14. The method according to claim 15, wherein the cells are resting B cells.

- 15 15. A method for increasing antigenicity of cells, comprising:
- contacting said cells with said multimeric TNFSF fusion proteins, wherein said cells are tumor cells or HIV positive cells.




Figure 1



Figure 2





Figure 3










Figure 4

Figure 5



**Figure 6**

**Figure 7**

## SEQUENCE LISTING

<110> Kornbluth, Richard S

<120> Multimeric forms of CD40L and other TNF family members

<130> TNFSF-collectin fusion proteins

<140> 60/111,471

<141> 1998-12-08

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 1552

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<220>

<221> misc\_feature

<222> (88)..(799)

<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>

<221> misc\_feature

<222> (801)..(1546)

<223> Human CD40 ligand extracellular region, including stalk.

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

- <221> CDS  
<222> (32)..(1444)  
  
<220>  
<223> Description of Artificial Sequence: Murine surfactant protein D (without the CRD) fused to the extracellular portion of human CD40L  
  
<300>  
<301> Spriggs, Melanie K.  
Armitage, Richard J.  
Strockbine, L  
Clifford, K N.  
Macduff, B M.  
Sato, T A.  
Maliszewski, C R.  
Fanslow, William C.  
<302> Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.  
<303> J. Exp. Med.  
<304> 176  
<305> 6  
<306> 1543-1550  
<307> 1992  
<313> 801 TO 1600  
  
<300>  
<301> Motwani, M  
White, R A.  
<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.  
<303> J. Immunol.  
<304> 155  
<305> 12  
<306> 5671-5677  
<307> 1995  
<313> 32 TO 800  
  
<400> 1  
gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg  
52  
Met Leu Pro Phe Leu Ser Met



1

5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag  
 100  
 Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys  
           10                          15                          20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt  
 148  
 Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys  
       25                          30                          35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga  
 196  
 Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg  
       40                          45                          50                          55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg  
 244  
 Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met  
                           60                          65                          70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga  
 292  
 Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly  
                           75                          80                          85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta  
 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
                           90                          95                          100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa  
 388  
 Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
       105                          110                          115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt  
 436  
 Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
       120                          125                          130                          135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg  
484

Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga  
532

Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga  
580

Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc  
628

Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa  
676

Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag  
724

Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu  
220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat  
772

Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga agg ttg gac aag ata  
820

Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Ile  
250 255 260

gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg aaa acg ata  
868

Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr Ile

265		270		275
cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg aac tgt gag				
916				
Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys Glu				
280		285		290 295
gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata atg tta aac				
964				
Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu Asn				
	300		305	310
aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa aaa ggt gat				
1012				
Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly Asp				
	315		320	325
cag aat cct caa att gcg gca cat gtc ata agt gag gcc agc agt aaa				
1060				
Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser Lys				
	330		335	340
aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac acc atg agc				
1108				
Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser				
	345		350	355
aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc gtt aaa aga				
1156				
Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg				
360		365		370 375
caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt tcc aat cgg				
1204				
Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg				
	380		385	390
gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc cta aag tcc				
1252				
Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys Ser				
	395		400	405

ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat acc cac agt  
1300

Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His Ser  
410 415 420

tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga gga gta ttt  
1348

Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val Phe  
425 430 435

gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act gat cca agc  
1396

Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro Ser  
440 445 450 455

caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta ctc aaa ctc  
1444

Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu  
460 465 470

tgaacagtgt caccttgacg gctgtggtgg agctgacgct gggagtcttc ataatacagc  
1504

acaggcttaa gcccaattat acactccaag gcatgtagaa ctggtacc  
1552

<210> 2

<211> 471

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine  
surfactant protein D (without the CRD) fused to  
the extracellular portion of human CD40L

<400> 2

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly

			35					40						45					
Arg	Asp	Gly	Arg	Asp	Gly	Arg	Glu	Gly	Pro	Arg	Gly	Glu	Lys	Gly	Asp				
	50					55					60								
Pro	Gly	Leu	Pro	Gly	Pro	Met	Gly	Leu	Ser	Gly	Leu	Gln	Gly	Pro	Thr				
65					70				75						80				
Gly	Pro	Val	Gly	Pro	Lys	Gly	Glu	Asn	Gly	Ser	Ala	Gly	Glu	Pro	Gly				
				85					90					95					
Pro	Lys	Gly	Glu	Arg	Gly	Leu	Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile				
			100					105					110						
Pro	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile				
	115						120					125							
Gly	Pro	Gln	Gly	Lys	Pro	Gly	Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly				
	130					135					140								
Glu	Val	Gly	Ala	Pro	Gly	Met	Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser				
145					150				155						160				
Thr	Gly	Pro	Lys	Gly	Glu	Arg	Gly	Ala	Pro	Gly	Val	Gln	Gly	Ala	Pro				
				165					170					175					
Gly	Asn	Ala	Gly	Ala	Ala	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Gln	Gly				
		180					185						190						
Ala	Pro	Gly	Ser	Arg	Gly	Pro	Pro	Gly	Leu	Lys	Gly	Asp	Arg	Gly	Val				
		195					200					205							
Pro	Gly	Asp	Arg	Gly	Ile	Lys	Gly	Glu	Ser	Gly	Leu	Pro	Asp	Ser	Ala				
	210					215					220								
Ala	Leu	Arg	Gln	Gln	Met	Glu	Ala	Leu	Lys	Gly	Lys	Leu	Gln	Arg	Leu				
225					230					235					240				
Glu	Val	Ala	Phe	Ser	His	Tyr	Gln	Lys	Ala	Ala	Leu	Phe	Pro	Asp	Gly				
				245					250					255					
His	Arg	Arg	Leu	Asp	Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp				
			260					265					270						

[illegible]

<210> 3

<211> 1574  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> 5'UTR  
<222> (7)..(31)  
<223> 5' UTR taken from rat sequence for surfactant protein D

<220>  
<221> sig\_peptide  
<222> (32)..(88)  
<223> Signal peptide from murine surfactant protein D

<220>  
<221> CDS  
<222> (32)..(1534)

<220>  
<221> misc\_feature  
<222> (32)..(800)  
<223> Murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>  
<221> misc\_feature  
<222> (801)..(1534)  
<223> Murine RANKL/TRANCE extracellular region, including stalk

<300>  
<301> Motwani, M  
White, R A.  
Guo, N  
Dowler, L L.  
Tauber, A I.  
Motwani, M  
<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.  
<303> J. Immunol.

<304> 155  
 <305> 12  
 <306> 5671-5677  
 <307> 1995  
 <313> 32 TO 800

<300>

<301> Anderson, D M.  
 Maraskovsky, E  
 Billingsley, W L.  
 Dougall, W C.

<302> A homologue of the TNF receptor and its ligand enhance  
 T-cell growth and dendritic-cell function.

<303> Nature

<304> 390

<305> 6656

<306> 175-179

<307> 1997

<313> 801 TO 1534

<400> 3

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg  
 52

Met Leu Pro Phe Leu Ser Met  
 1 5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag  
 100

Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys  
 10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt  
 148

Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys  
 25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga  
 196

Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg  
 40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg  
 244



Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met  
                     60                    65                    70  
 ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga  
 292  
 Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly  
                     75                    80                    85  
 gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta  
 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
                     90                    95                    100  
 agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa  
 388  
 Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
                     105                    110                    115  
 ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt  
 436  
 Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
                     120                    125                    130                    135  
 cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg  
 484  
 Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
                     140                    145                    150  
 caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga  
 532  
 Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
                     155                    160                    165  
 ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga  
 580  
 Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
                     170                    175                    180  
 cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc  
 628  
 Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
                     185                    190                    195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa  
 676  
 Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
 200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag  
 724  
 Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu  
 220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat  
 772  
 Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
 235 240 245

cag aaa gct gca ttg ttc cct gat ggt cga gcg cag atg gat cct aac  
 820  
 Gln Lys Ala Ala Leu Phe Pro Asp Gly Arg Ala Gln Met Asp Pro Asn  
 250 255 260

aga ata tca gaa gac agc act cac tgc ttt tat aga atc ctg aga ctc  
 868  
 Arg Ile Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu  
 265 270 275

cat gaa aac gca ggt ttg cag gac tcg act ctg gag agt gaa gac aca  
 916  
 His Glu Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr  
 280 285 290 295

cta cct gac tcc tgc agg agg atg aaa caa gcc ttt cag ggg gcc gtg  
 964  
 Leu Pro Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val  
 300 305 310

cag aag gaa ctg caa cac att gtg ggg cca cag cgc ttc tca gga gct  
 1012  
 Gln Lys Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala  
 315 320 325

cca gct atg atg gaa ggc tca tgg ttg gat gtg gcc cag cga ggc aag  
 1060  
 Pro Ala Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys

330	335	340
cct gag gcc cag cca ttt gca cac ctc acc atc aat gct gcc agc atc 1108		
Pro Glu Ala Gln Pro Phe	Ala His Leu Thr Ile	Asn Ala Ala Ser Ile
345	350	355
cca tcg ggt tcc cat aaa gtc act ctg tcc tct tgg tac cac gat cga 1156		
Pro Ser Gly Ser His	Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg	
360	365	370
ggc tgg gcc aag atc tct aac atg acg tta agc aac gga aaa cta agg 1204		
Gly Trp Ala Lys	Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg	
	380	385
gtt aac caa gat ggc ttc tat tac ctg tac gcc aac att tgc ttt cgg 1252		
Val Asn Gln Asp Gly Phe Tyr Tyr	Leu Tyr Ala Asn Ile Cys Phe Arg	
	395	400
cat cat gaa aca tcg gga agc gta cct aca gac tat ctt cag ctg atg 1300		
His His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met		
410	415	420
gtg tat gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg 1348		
Val Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu		
425	430	435
atg aaa gga ggg agc acg aaa aac tgg tcg ggc aat tct gaa ttc cac 1396		
Met Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His		
440	445	450
ttt tat tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa 1444		
Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu		
	460	465
		470

gaa att agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa  
1492

Glu Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln  
475 480 485

gat gcg acg tac ttt ggg gct ttc aaa gtt cag gac ata gac  
1534

Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
490 495 500

tgagactcat ttcgtggaac attagcggcc gctaaactat  
1574

<210> 4

<211> 501

<212> PRT

<213> Artificial Sequence

<400> 4

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
 130 135 140  
 Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
 145 150 155 160  
 Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
 165 170 175  
 Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
 180 185 190  
 Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
 195 200 205  
 Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
 210 215 220  
 Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
 225 230 235 240  
 Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
 245 250 255  
 Arg Ala Gln Met Asp Pro Asn Arg Ile Ser Glu Asp Ser Thr His Cys  
 260 265 270  
 Phe Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Gly Leu Gln Asp Ser  
 275 280 285  
 Thr Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys Arg Arg Met Lys  
 290 295 300  
 Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile Val Gly  
 305 310 315 320  
 Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly Ser Trp Leu  
 325 330 335  
 Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro Phe Ala His Leu  
 340 345 350

Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly Ser His Lys Val Thr Leu  
 355 360 365  
 Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr  
 370 375 380  
 Leu Ser Asn Gly Lys Leu Arg Val Asn Gln Asp Gly Phe Tyr Tyr Leu  
 385 390 395 400  
 Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser Gly Ser Val Pro  
 405 410 415  
 Thr Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser Ile Lys  
 420 425 430  
 Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr Lys Asn Trp  
 435 440 445  
 Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe  
 450 455 460  
 Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln Val Ser Asn Pro  
 465 470 475 480  
 Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys  
 485 490 495  
 Val Gln Asp Ile Asp  
 500

<210> 5

<211> 1477

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Murine  
 surfactant protein D (except CRD) fused to the  
 extracellular domain of murine CD40 ligand

<220>

<221> 5'UTR  
<222> (7)..(31)  
<223> 5' UTR from rat surfactant protein D

<220>  
<221> sig\_peptide  
<222> (32)..(88)  
<223> Signal peptide from murine surfactant protein D

<220>  
<221> CDS  
<222> (32)..(1441)

<220>  
<221> misc\_recomb  
<222> (88)..(799)  
<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>  
<221> misc\_feature  
<222> (800)..(1441)  
<223> Murine CD40 ligand extracellular region, including stalk

<300>  
<301> Motwani, M  
White, R A.  
Guo, N  
Dowler, L L.  
Tauber, A I.  
Motwani, M  
<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.  
<303> J. Immunol.  
<304> 155  
<305> 12  
<306> 5671-5677  
<307> 1995  
<313> 32 TO 800

&lt;300&gt;

&lt;301&gt; Armitage, R

Fanslow, W

Sato, T A.

Clifford, K N.

<302> Molecular and biological characterization of a murine  
ligand for CD40

&lt;303&gt; Nature

&lt;304&gt; 357

&lt;305&gt; 6373

&lt;306&gt; 80-82

&lt;307&gt; 1992

&lt;313&gt; 801 TO 1441

&lt;400&gt; 5

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg  
52Met Leu Pro Phe Leu Ser Met  
1 5ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag  
100Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys  
10 15 20agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt  
148Ser Leu Ser Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys  
25 30 35agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga  
196Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg  
40 45 50 55gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg  
244Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met  
60 65 70ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga  
292

Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly



	75		80		85										
gag	aat	ggc	tct	gct	ggc	gaa	cct	gga	cca	aag	gga	gaa	cgt	gga	cta
340															
Glu	Asn	Gly	Ser	Ala	Gly	Glu	Pro	Gly	Pro	Lys	Gly	Glu	Arg	Gly	Leu
	90					95						100			
agt	gga	cct	cca	gga	ctt	cca	ggt	att	cct	ggt	cca	gct	ggg	aaa	gaa
388															
Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly	Pro	Ala	Gly	Lys	Glu
	105					110					115				
ggt	ccc	tct	ggg	aag	cag	ggg	aac	ata	gga	cct	caa	ggc	aaa	cca	ggt
436															
Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile	Gly	Pro	Gln	Gly	Lys	Pro	Gly
120					125					130					135
cct	aaa	gga	gag	gct	ggg	ccc	aaa	gga	gaa	gta	ggt	gct	cct	ggc	atg
484															
Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly	Glu	Val	Gly	Ala	Pro	Gly	Met
				140					145					150	
caa	gga	tct	aca	ggg	gca	aaa	ggc	tcc	aca	ggc	ccc	aag	gga	gaa	aga
532															
Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser	Thr	Gly	Pro	Lys	Gly	Glu	Arg
			155					160					165		
ggt	gcc	cct	ggt	gtg	caa	gga	gcc	cca	ggg	aat	gct	gga	gca	gca	gga
580															
Gly	Ala	Pro	Gly	Val	Gln	Gly	Ala	Pro	Gly	Asn	Ala	Gly	Ala	Ala	Gly
		170					175					180			
cct	gcc	gga	cct	gcc	ggt	cca	cag	gga	gct	cca	ggt	tcc	agg	ggg	ccc
628															
Pro	Ala	Gly	Pro	Ala	Gly	Pro	Gln	Gly	Ala	Pro	Gly	Ser	Arg	Gly	Pro
	185					190					195				
cca	gga	ctc	aag	ggg	gac	aga	ggt	gtt	cct	gga	gac	aga	gga	atc	aaa
676															
Pro	Gly	Leu	Lys	Gly	Asp	Arg	Gly	Val	Pro	Gly	Asp	Arg	Gly	Ile	Lys
200					205					210					215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag  
724

Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu  
220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat  
772

Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga aga ttg gat aag gtc  
820

Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Val  
250 255 260

gaa gag gaa gta aac ctt cat gaa gat ttt gta ttc ata aaa aag cta  
868

Glu Glu Glu Val Asn Leu His Glu Asp Phe Val Phe Ile Lys Lys Leu  
265 270 275

aag aga tgc aac aaa gga gaa gga tct tta tcc ttg ctg aac tgt gag  
916

Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser Leu Leu Asn Cys Glu  
280 285 290 295

gag atg aga agg caa ttt gaa gac ctt gtc aag gat ata acg tta aac  
964

Glu Met Arg Arg Gln Phe Glu Asp Leu Val Lys Asp Ile Thr Leu Asn  
300 305 310

aaa gaa gag aaa aaa gaa aac agc ttt gaa atg caa aga ggt gat gag  
1012

Lys Glu Glu Lys Lys Glu Asn Ser Phe Glu Met Gln Arg Gly Asp Glu  
315 320 325

gat cct caa att gca gca cac gtt gta agc gaa gcc aac agt aat gca  
1060

Asp Pro Gln Ile Ala Ala His Val Val Ser Glu Ala Asn Ser Asn Ala  
330 335 340

gca tcc gtt cta cag tgg gcc aag aaa gga tat tat acc atg aaa agc  
1108

Ala Ser Val Leu Gln Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys Ser

345                                      350                                      355  
 aac ttg gta atg ctt gaa aat ggg aaa cag ctg acg gtt aaa aga gaa  
 1156  
 Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Glu  
 360                                      365                                      370                                      375  
 gga ctc tat tat gtc tac act caa gtc acc ttc tgc tct aat cgg gag  
 1204  
 Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe Cys Ser Asn Arg Glu  
    380                                      385                                      390  
 cct tcg agt caa cgc cca ttc atc gtc ggc ctc tgg ctg aag ccc agc  
 1252  
 Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu Trp Leu Lys Pro Ser  
    395                                      400                                      405  
 att gga tct gag aga atc tta ctc aag gcg gca aat acc cac agt tcc  
 1300  
 Ile Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala Asn Thr His Ser Ser  
    410                                      415                                      420  
 tcc cag ctt tgc gag cag cag tct gtt cac ttg ggc gga gtg ttt gaa  
 1348  
 Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu Gly Gly Val Phe Glu  
    425                                      430                                      435  
 tta caa gct ggt gct tct gtg ttt gtc aac gtg act gaa gca agc caa  
 1396  
 Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val Thr Glu Ala Ser Gln  
 440                                      445                                      450                                      455  
 gtg atc cac aga gtt ggc ttc tca tct ttt ggc tta ctc aaa ctc  
 1441  
 Val Ile His Arg Val Gly Phe Ser Ser Phe Gly Leu Leu Lys Leu  
    460                                      465                                      470  
 tgaacagtgc gctgtcctag gctgcagcag ggtacc  
 1477

&lt;210&gt; 6

&lt;211&gt; 470

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Description of Artificial Sequence: Murine  
surfactant protein D (except CRD) fused to the  
extracellular domain of murine CD40 ligand

&lt;400&gt; 6

```

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly
 1               5               10               15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn
      20               25               30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly
      35               40               45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp
      50               55               60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr
      65               70               75               80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly
      85               90               95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile
      100              105              110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile
      115              120              125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly
      130              135              140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser
      145              150              155              160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro
      165              170              175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly
      180              185              190

```

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
 195 200 205  
 Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
 210 215 220  
 Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
 225 230 235 240  
 Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
 245 250 255  
 His Arg Arg Leu Asp Lys Val Glu Glu Glu Val Asn Leu His Glu Asp  
 260 265 270  
 Phe Val Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser  
 275 280 285  
 Leu Ser Leu Leu Asn Cys Glu Glu Met Arg Arg Gln Phe Glu Asp Leu  
 290 295 300  
 Val Lys Asp Ile Thr Leu Asn Lys Glu Glu Lys Lys Glu Asn Ser Phe  
 305 310 315 320  
 Glu Met Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val Val  
 325 330 335  
 Ser Glu Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys Lys  
 340 345 350  
 Gly Tyr Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys  
 355 360 365  
 Gln Leu Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val  
 370 375 380  
 Thr Phe Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val  
 385 390 395 400  
 Gly Leu Trp Leu Lys Pro Ser Ile Gly Ser Glu Arg Ile Leu Leu Lys  
 405 410 415  
 Ala Ala Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val

				420					425							430
His	Leu	Gly	Gly	Val	Phe	Glu	Leu	Gln	Ala	Gly	Ala	Ser	Val	Phe	Val	
		435					440					445				
Asn	Val	Thr	Glu	Ala	Ser	Gln	Val	Ile	His	Arg	Val	Gly	Phe	Ser	Ser	
	450					455					460					
Phe	Gly	Leu	Leu	Lys	Leu											
465					470											

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07380

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>												
IPC(7) : C07K 14/00; A61K 38/00												
US CL : 435/69.1; 530/324; 514/2												
According to International Patent Classification (IPC) or to both national classification and IPC												
<b>B. FIELDS SEARCHED</b>												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/69.1; 530/324; 514/2; 536/23.5; 435/455												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet												
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
A	GIRES, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. October 1999, Vol. 16, No. 20, pages 6131-6140, especially page 6131.	1-15										
A	PISON, U. et al. Host defence capacities of pulmonary surfactant: evidence for 'non-surfactant' functions of the surfactant system. Eur. J. Clin. Inv. September 1994, Vol. 24, No. 9, pages 586-599.	1-15										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 26 July 2000 (26.07.2000)		Date of mailing of the international search report 18 SEP 2000										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer Eyler Yvonne Telephone No. 703-308-0196										

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07380

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 1-12  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
These claims are drawn to polypeptides and nucleic acids, but no computer-readable sequence information has been submitted. The search for these claims was therefore based on text alone.
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US00/07380

**Continuation of B. FIELDS SEARCHED Item 3: STN, EAST**  
search terms: TNF, CD40L, collectin, multimer